Volex (AIM: VLX) upgrades FY2026 revenue to at least $1.22bn as AI data centre demand doubles and board eyes Main Market move
Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?
Read More 2 minute read Pharma Industry News Rohatyn Group completes investment in Croatian CRO Optimapharm The Rohatyn Group (TRG), a US asset management firm focusing on emerging markets, has completed an investment in… bypharmanewsdailyMay 13, 2020
